Efficacy and safety of Janus kinase inhibitors in patients with difficult-to-treat rheumatoid arthritis | Synapse

⌘+K

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Preferable outcome of Janus kinase inhibitors for a group of difficult-to-treat rheumatoid arthritis patients: from the FIRST RegistryRegistry Study · 2022 · 77 citations
2Effectiveness of janus kinase inhibitors compared with biologic disease modifying anti‐rheumatic drugs on pain reduction in rheumatoid arthritis2024 · 3 citations
3Long-Term Safety and Efficacy of Janus kinase (JAK) Inhibitors in the Treatment of Rheumatoid Arthritis2024 · 1 citations
4From concept to practice: real-world safety of JAK inhibitors in rheumatoid arthritis treatmentOriginal Research · 2026 · 1 citations
5POS0673 THE COMPARATIVE OBSERVATIONAL STUDY ABOUT EFFICACY, SAFETY AND DRUG SURVIVAL RATE OF JANUS KINASE INHIBITORS BETWEEN DIFFICULT-TO-TREAT RHEUMATOID ARTHRITIS (D2TRA) AND NON-D2TRA2024

More from Modern Rheumatology

More from Osaka City General Hospital